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Axons can be several orders of magnitude longer than neural somas, presenting
logistical difficulties in cargo trafficking and structural maintenance. Keeping the axon
compartment well supplied with energy also presents a considerable challenge; even
seemingly subtle modifications of metabolism can result in functional deficits and
degeneration. Axons require a great deal of energy, up to 70% of all energy used by
a neuron, just to maintain the resting membrane potential. Axonal energy, in the form
of ATP, is generated primarily through oxidative phosphorylation in the mitochondria.
In addition, glial cells contribute metabolic intermediates to axons at moments of high
activity or according to need. Recent evidence suggests energy disruption is an early
contributor to pathology in a wide variety of neurodegenerative disorders characterized
by axonopathy. However, the degree to which the energy disruption is intrinsic to the
axon vs. associated glia is not clear. This paper will review the role of energy availability
and utilization in axon degeneration in glaucoma, a chronic axonopathy of the retinal
projection.
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METABOLIC VULNERABILITY IN GLAUCOMA
Glaucoma is the leading cause of irreversible blindness worldwide (Tham et al., 2014). It blinds
through the dysfunction and degeneration of retinal ganglion cell (RGC) axons that carry visual
information from the eye to the brain (Calkins and Horner, 2012; Casson et al., 2012). There is
emerging evidence for a critical role for energy management in the axon degeneration observed
in this disease. In our work, we have been using the DBA/2J mouse model of glaucoma, an inbred
strain that develops increased intraocular pressure (IOP) secondary to an iris pigment dispersion
disease (John et al., 1998; Anderson et al., 2002). IOP is the main modifiable risk factor in primary
open angle glaucoma, and lowering IOP is the mainstay of treatment. Increased IOP in the DBA/2J
(D2) leads to optic neuropathy and eventual RGC death in a manner that emulates human patients
with the most common forms of glaucoma, with pathology developing slowly over time (John et al.,
1998), and occurring in contiguous retinal regions (Jakobs et al., 2005). IOP elevations in D2 mice
are similar in scale to human patients, and the magnitude of these increases correlates with axon
degeneration (Inman et al., 2006).
The potential role of energy availability and utilization in glaucoma became apparent through
optic nerve physiology experiments. We measured compound action potential (CAP), the
summation of all action potentials after stimulation, in freshly isolated D2 optic nerves. CAP
amplitude decreased significantly by 6 months of age (Baltan et al., 2010), prior to measurable axon
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structural pathology (Inman et al., 2006) or axon transport
deficit (Dengler-Crish et al., 2014) in this model. The reduction
in elicited neural activity was inversely correlated with IOP
elevation in the D2; the higher the IOP exposure within
an age group, the lower the CAP amplitude (Baltan et al.,
2010). Notably, there was no difference in CAP latency or
duration in the D2 at 6 or 10 months, and no impact of
the K+ channel blocker 4-aminopyridine. Both observations
argue against significant changes in myelination as observed
in multiple sclerosis-associated optic neuropathy in humans
(Chan, 2002). However, when D2 optic nerves were subjected to
oxygen-glucose deprivation and then allowed to recover, nerves
from 6-month-old mice in the high IOP group demonstrated
impaired recovery when compared to their low IOP companions.
By 10 months of age, however, D2 optic nerves could not
sustain recovery from oxygen-glucose deprivation in any mice,
independent of IOP history. These results suggested that both
IOP and age influence energy reserves in this pathology. To
corroborate energy depletion, ATP measurements from D2
optic nerve showed significantly decreased ATP in the high
IOP groups within each age, and significantly depleted ATP
levels when comparing 6 to 10-month-olds within IOP group
(see Figure 1 for summary) (Baltan et al., 2010). The low
ATP and clear lack of energy reserve in the D2 optic nerve
with increased IOP suggested glaucoma-associated metabolic
dysfunction. Strikingly, the metabolic dysfunction in the axon
occurs quite early in the D2, prior to overt structural changes
in the optic nerve. This suggests that resolution of the metabolic
dysfunction could prevent axon degeneration and preserve visual
function.
The observations of a potential metabolic dysfunction in
glaucoma raise a number of interesting possibilities about the
mechanism of pathophysiology. Several fundamental concepts
have implications for how glaucoma could be managed and what
might be fruitful therapeutic approaches to combat the disease:
(1) how energy is produced and utilized in axons, (2) how
energy is associated with axon degeneration, (3) the nature of
axon degeneration in glaucoma, and (4) how axon degeneration
might be prevented. As discussed below, the entry points for the
final destruction of the axon vary between neurodegenerative
disorders but have much in common beyond initiation. The
focus here is energy depletion, which arises from a number of
circumstances, including ischemia, mitochondrial dysfunction,
age-related changes in the NAD+-sirtuin-PGC-1α axis, loss of
axon support factors, and activation of axon degeneration factors.
Below we review the current understanding of energy production
in white matter and possible intervention points in glaucoma
and, by extension, other chronic axonopathies.
ENERGY IN AXONS
Energy is produced both within axons and around them using
substrates delivered by the circulation and glial cells. Axons
obtain most of their energy from ATP through oxidative
phosphorylation in mitochondria. Glial cells that contact axons
(oligodendrocytes and astrocytes) are capable of providing
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FIGURE 1 | Optic nerve ATP levels in the DBA/2J model of glaucoma at
6 and 10 months of age, separated into low and high intraocular
pressure (IOP) groups. Optic nerves were rapidly isolated then flash frozen in
liquid nitrogen until assay. Upon thaw, the optic nerve was cut into small
pieces while in 10% HClO4, then homogenized by sonication, and centrifuged
at 4,500 rpm for 10 min at 4◦C. The supernatant was collected, neutralized
with 30 µl of 2.5 M KOH, then centrifuged at 14,000 rpm for 10 min at 4◦C.
The precipitate was removed, and supernatant kept on ice. Total ATP
concentration was measured using the ATP bioluminescence assay kit
(Roche), based on the ATP dependence of luciferase catalyzed oxidation of
luciferin. Samples were diluted and mixed with the luciferase reagent and then
absorbance was measured at 560 nm. Blank values were subtracted from the
raw data, and ATP concentrations were calculated from a log–log plot of the
standard curve data and normalized by the protein concentration. The values
are expressed as millimoles of ATP per milligrams of protein. There was a
significant difference in ATP levels in low vs. high IOP groups (t-test, #p =
0.012 for 6 m; *p = 0.049 for 10 m), and a significant difference in the ATP
levels across 6m vs. 10m at low (t-test, ∧p = 0.014) and high (t-test, §p =
0.028) IOP. Above: representative compound action potential traces from each
group; below: average IOP for each group. Adapted from Baltan et al. (2010).
energy substrates to axons as well. This energy is necessary for
axon function.
Within Axons: Oxidative Phosphorylation
and Glycolysis
The central nervous system prefers glucose as its substrate;
glucose enters the brain (and retina and optic nerve) through
glucose transporters. Neurons express GLUT3, a high-affinity
glucose transporter (Maher et al., 1991), while astrocytes and
endothelial cells express GLUT1 (Garcia-Caceres et al., 2016).
Both GLUT3 and GLUT1 can be upregulated through insulin
signaling (Simpson et al., 2008). Glucose is converted through
glycolysis to pyruvate; the resultant pyruvate is fed into the Krebs
cycle in mitochondria for the generation of ATP. Glucose in
axons can also be used to produce reducing equivalents like
NADPH via the pentose-phosphate pathway in order to maintain
redox balance (Stincone et al., 2015). Neurons are highly
oxidative and dependent on their mitochondria. ATP produced
by mitochondria in the average ON axon can comfortably sustain
the observed firing rate of action potentials, the maintenance of
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the resting potential, and maintenance processes, according to a
computational model that drew on published values for rat CNS
(Harris and Attwell, 2012). The model indicated mitochondria
could support all optic nerve axons using roughly 50% of the ATP
generation capacity. There is only a calculated ATP shortfall for
small axons, those below 0.8 µm in diameter (Harris and Attwell,
2012). In humans, normal optic nerve axon mean diameter
ranges from 0.72 ± 0.07 µm (Mikelberg et al., 1989), to 0.96 ±
0.07 µm (Quigley et al., 1988), and 1.00 ± 0.06 µm (Jonas et al.,
1990). Even within these ranges, a significant portion of the axons
in the human optic nerve are likely to experience ATP shortfall
if the model accurately predicts energy availability. The same is
true for mouse, with a frequency distribution of optic nerve fiber
diameter that peaks at 0.7–0.9 µm; 50.4% of axons are 0.9 um in
diameter or less (Honjin et al., 1977), suggesting that there could
also be a mitochondrial-derived ATP shortfall in a large subset of
axons. The energy sufficiency calculations also depend upon the
axon having enough access to glucose.
In general, there are adequate concentrations of GLUT3, the
primary glucose transporter in neuronal membranes (Maher
et al., 1991), to provide the necessary glucose levels to axons
(Harris and Attwell, 2012). These estimates assume glucose
diffusion to the middle of an internode quickly (see Figure 2); rat
internodes average 240µm (Ransom et al., 1991) while internode
lengths inmouse ON average 110µm (O’Meara et al., 2013). This
internode length suggests glucose will readily diffuse; however,
the predicted ATP shortfall in axons below 0.8 µm in diameter
indicates a potential vulnerability of small axons. Small axons
have light myelination, shorter internodes, slow conduction rates
(Hursh, 1939), and more sparse mitochondria (Perge et al.,
2009; Ohno et al., 2011). It has recently been demonstrated that
glucose transporters are upregulated in response to activity in
mouse myelinated axons (Saab et al., 2016), a potential solution
to the possible lack of glucose in small axons. There are two
caveats to this interpretation, however: The glucose transporters
were upregulated in oligodendrocytes, not axons; and protein
upregulation is not a dynamic response to momentary need.
Axons likely rely on alternatives to glucose for maintenance of
function.
Around Axons: Glial-Derived Energy
Axons may be supplied with metabolic intermediates from
astrocytes and oligodendrocytes to address potential shortfalls
from glucose transport and diffusion. Several early studies
demonstrated metabolic coupling between neuronal and glial
compartments (Hamberger and Hyden, 1963; Pevzner, 1971,
1972). Glia-to-neuron energy substrate transfer was also revealed
in early work on metabolic coupling between glia and neurons
in the honeybee retina, indicating that glial cells released alanine
that was taken up and metabolized by photoreceptor neurons
(Tsacopoulos and Magistretti, 1996). In the mammalian CNS,
glia mainly transfer monocarboxylates—L-lactate, pyruvate, or
ketone bodies—rather than alanine, to neurons (Brown et al.,
2003). The initial support for energy transfer from glia to
axons came from studies of optic nerve explants that could
maintain CAPs for approximately 30 min in the absence of
glucose (Stys et al., 1991; Wender et al., 2000). Further study
of optic nerve showed that CAP maintenance was dependent
on transport of lactate (Wender et al., 2000; Tekkök et al.,
2005). The critical evidence supporting intracellular metabolic
substrate transfer is based on a number of observations,
including: (1) the ability of glial cells to release L-lactate from
their glycogen stores (Dringen et al., 1993), (2) the ability of
neurons to take up L-lactate (Bouzier-Sore et al., 2003), (3)
the cellular distribution of lactate dehydrogenase enzyme that
converts lactate to pyruvate (Bittar et al., 1996), and (4) the
cellular localization of monocarboxylate transporters (MCTs)
within the CNS (Koehler-Stec et al., 1998; Pierre et al., 2002).
FIGURE 2 | Axon schematic showing the distribution of glucose transporters (GLUT), and monocarboxylate transporters (MCT) in the axon, astrocytes
and oligodendrocytes. GLUTs move glucose into the cell, while MCTs transport monocarboxylates such as lactate, pyruvate, and β-hydroxybutyrate. Glia express
MCT1 and MCT4, while axons express MCT2. The kinetics of the MCTs are such that MCT1 is best suited for lactate export and MCT2 for lactate uptake because of
its higher affinity for lactate (see text). The node of Ranvier is concentrated with ion channels (not shown) necessary for saltatory conduction. Astrocytes can interface
with the axon at the node of Ranvier. Oligodendrocytes myelinate the axon; the region between nodes of Ranvier is the internode.
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Mounting evidence from different experimental studies indicates
that oligodendrocytes and astrocytes significantly contribute to
metabolic substrate transfer for axonal metabolic support.
Lactate, a glycolytic end product, can be converted to pyruvate
for utilization in the Krebs cycle (Figure 3). Evidence from
many different experiments indicates that lactate is an efficient
oxidative energy substrate for neurons (Pellerin et al., 1998).
The conversion of lactate to pyruvate is catalyzed by lactate
dehydrogenase (LDH), and requires NAD+ as a cofactor. Cells
that produce lactate glycolytically, like astrocytes, are abundant
in one LDH isozyme, while cells that use lactate as a substrate,
including neurons, are enriched in another (Tsacopoulos and
Magistretti, 1996). Lactate is transported between glia and
neurons through the monocarboxylate transporters (MCTs).
MCTs are bidirectional extracellular membrane channels that
transport lactate, pyruvate, and ketone bodies across the
membrane depending on their concentration gradient (Pierre
and Pellerin, 2005). The MCTs work by first binding a proton
then one molecule of lactate; the transporter undergoes a
conformational change that releases the proton and the lactate
on the other side of the membrane (Dubinsky and Racker, 1978).
MCT isoforms differ in their substrate-binding affinities and
kinetics, making MCT1 best suited for lactate export and MCT2
for lactate uptake. Perhaps unsurprisingly, MCT1 is expressed
preferentially in oligodendrocytes and astrocytes (Lee et al.,
2012), while MCT2 is expressed in neurons and axons (Pierre
et al., 2002; Simpson et al., 2007), and MCT4 is expressed in
astrocytes (Rafiki et al., 2003). MCT2 has a much greater affinity
than MCT1 or MCT4 for lactate and pyruvate (Simpson et al.,
2007).
Glial Glycolysis Supports Axons
Glial cells and neurons form a metabolic unit in the CNS,
with glial cells providing energy substrates that ensure neural
function. In Drosophila, neurons die when glial cell glycolysis
is impaired, indicating that glycolysis is essential to neuron
survival (Volkenhoff et al., 2015). The metabolic unit is
supported by communication among cells; axon firing can lead
FIGURE 3 | Conversion of ketone bodies, including lactate and
β-hydroxybutyrate (β-HB), intermediates that can be utilized in Krebs
cycle. (A) Lactate conversion to pyruvate is catalyzed by lactate
dehydrogenase and requires NAD+. The reaction is reversible. Pyruvate is
oxidized to acetyl-CoA, using NAD+ and giving off NADH and CO2. (B) β-HB
can be utilized in Krebs cycle after a multi-step conversion reaction that results
in the formation of two molecules of acetyl-CoA for every molecule of β-HB.
to upregulation of glucose transporter-1 in oligodendrocytes
in mouse (Saab et al., 2016). Once fortified with additional
glucose, oligodendrocytes release lactate, thereby maintaining
energy supplies tomyelinated axons in the optic nerve.Moreover,
evidence from multiple sclerosis patient tissue suggests that
oligodendrocytes in low glucose conditions decrease their
lactate release (Rone et al., 2016), possibly imperiling myelin
maintenance but allowing cell survival. This suggests that glia are
responsive to axon activity through greater release of metabolic
substrate, but they have limits.
Glycogen
Astrocytes have glycogen stores that are capable of being
mobilized to provide glucose or lactate to axons (Pellerin
et al., 1998; Erlichman et al., 2008). Mobilized glycogen allows
for continued optic nerve CAP generation when mouse optic
nerves are deprived of glucose (Wender et al., 2000). In
vitro evidence suggests that lactate derived from glycogen
breakdown is preferentially exported (Sickmann et al., 2005).
The glycogen stores get broken down into lactate, which
gets transferred to and used by axons, as shown by CAP
failure when lactate transporters are blocked in periods of
aglycemia in mouse optic nerve (Wender et al., 2000; Tekkök
et al., 2005). Blocking glycogen breakdown accelerated CAP
failure in optic nerve subjected to high-frequency stimulation
(Brown et al., 2005). Furthermore, neuronal function can be
maintained and neuronal death averted during hypoglycemia
by increasing astrocytic glycogen stores in rat brain (Suh et al.,
2007). These data demonstrate that lactate from glial glycogen
stores can and will be used by axons under stress. In brain
parenchyma, astrocytes have unique morphological structures
and phenotypical features, which ideally position them to
sense neuronal activity (Lundgaard et al., 2014) and respond
with the suitable metabolic substrate to their surrounding
microenvironment (Rouach et al., 2008). Is something similar
at work in white matter, between astrocytes and axons? Gap
junctions known to connect astrocytes and oligodendrocytes
(Orthmann-Murphy et al., 2007) could facilitate movement of
glucose or lactate from astrocyte to oligodendrocyte, thereby
providing lactate or other substrates directly through the axon-
facing MCT-1 on oligodendrocytes. Alternatively, astrocytes are
known to contact nodes of Ranvier (Serwanski et al., 2017) and
may deliver metabolic substrates directly.
Energy and Axon Degeneration
Axon degeneration is a complex process that can initiate from
different neuronal compartments, e.g., the soma, terminal
boutons, or the axon itself. Regardless, the initial stages of
neurodegeneration often manifest in the axon compartment.
Axon degeneration mechanisms can share three common
elements: intra-axonal Ca++ dysregulation, axon transport
deficits, and mitochondrial dysfunction (Fagiolini et al., 1997;
Stys, 2004). Both axon transport deficits and mitochondrial
dysfunction are energy-related pathologies. For example,
molecular motors require energy for axon transport. Earlier
work on this subject posited that mitochondrial dysfunction
would preclude axon transport until it was demonstrated that
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molecular motors can use extra-mitochondrial sources of energy
(Zala et al., 2013). This may dissociate axon transport deficit
from mitochondria with regards to ATP demand; however,
pathological change in mitochondrial dynamics can alter
transport through other mechanisms (Crish and Calkins, 2011;
Misko et al., 2012). Metabolic dysfunction could contribute to
axon transport deficit, independent of mitochondria, through
lack of substrate delivery to the axon. Anterograde axon transport
deficit is known to be an important alteration in the pathology of
glaucoma (Crish et al., 2010; Dengler-Crish et al., 2014). As will
be discussed below, axon transport is required to maintain axon
structure and function as well as traffic survival factors for the
neuron (see Vrabec and Levin, 2007; Milde et al., 2013).
Mitochondria and Degeneration
Investigation into the mechanisms of axon degeneration
underscores the central role of energy availability and
mitochondria in keeping the axon compartment alive.
For example, injured axons in zebrafish rapidly degenerate
without mitochondria (Campbell et al., 2014). In C. elegans,
mitochondrial targeting to axons can protect them
from degeneration (Rawson et al., 2014). Similarly,
releasing mitochondria from their syntaphilin tethers in
axotomizedcultured cortical mouse axons can rescue energy
deficits (Zhou et al., 2016), demonstrating the importance
of ATP homeostasis to axon survival after injury. Some have
determined mitochondria to be the site of axon protection
(Avery et al., 2012), though preventing mitochondrial transport
into axons prior to injury slowed, but did not stop, the course of
axon degeneration in a Drosophila axotomy model (Kitay et al.,
2013). Depolarizing mitochondria does not increase the rate of
Wallerian degeneration in superior cervical ganglion axons in
vitro, indicating that degeneration-associated Ca++ increases
are extra-mitochondrial (Loreto et al., 2015). Axon regeneration,
quite separate from degeneration, in mouse RGC axons (Cartoni
et al., 2016) and C. elegans nerve cord axons (Han et al., 2016),
does require mitochondria.
Glial Lactate Critical for Axon Survival
Recent experimental data demonstrates that MCTs are critical
for maintaining axon health and integrity. Mice with 50% lower
than normal MCT1 expression developed axonopathy in the
optic nerve, suggesting that axons are quite sensitive to reduction
in the provision of lactate from oligodendrocytes (Lee et al.,
2012). Neurons in organotypic cultures could not survive without
MCT1, and axons without it degenerated. MCT1 was also shown
to be reduced in patients with amyotrophic lateral sclerosis (ALS)
and in amousemodel of ALS (Lee et al., 2012). Deletion ofMCT1
in oligodendrocytes substantially reduces the availability of local
energy metabolites to the axon (Lee et al., 2012), potentially
affecting the axonal energy-dependent processes such as axonal
transport (Nave, 2010).
The crucial role of MCT1, a mover of energy substrate
from the oligodendroglial compartment to axons, in axon
function and survival spurred investigation into the regulation
of energy exchange between oligodendrocyte and neuron (Saab
et al., 2016). Stimulation of oligodendroglial NMDA receptors
in response to axonal glutamate release upregulates glucose
transporter GLUT1 in the oligodendrocyte. Increased uptake of
glucose in the myelin as a result of GLUT1 expression ensures
greater glucose delivery to the oligodendrocytes at a time when
the axon is engaged in high spiking activity, thereby establishing
a path to greater lactate release by the oligodendrocyte to
the myelinated axon. Axons recovered from oxygen-glucose
deprivation better with lactate than with glucose, indicating the
oligodendrocytes were not merely passing along glucose to the
axons (Saab et al., 2016).
A multi-pronged approach to supplying axons with energy, as
outlined in the section on energy described above, is necessary
because of the dire consequences of axonal energy depletion.
Axons expend the bulk of their energy budget on the Na+-K+
ATPase which moves these ions across the axolemma during and
after action potential firing (Ritchie, 1967). Without sufficient
energy for Na+-K+ ATPase function, axons experience Na+
and Ca++ overload and then structural decline when Ca++-
dependent proteases such as calpain (and potentially others) lay
waste to the cytoskeleton, disrupting axon transport, physiology,
and other vital axon maintenance processes. Extracellular Ca++
influx is both necessary and sufficient for axon degeneration
(Court and Coleman, 2012); it is part of a “final common
pathway” for various mechanisms of axon degeneration such as
developmental axon pruning and Wallerian degeneration (Yang
et al., 2013); reviewed in (Stirling and Stys, 2010; Tsutsui and Stys,
2013; Conforti et al., 2014).
Energy and Mechanisms of Axon
Degeneration: Wallerian
A role for energy in the mechanism of axon degeneration
emerged from research into the mechanism of axon protection
in the Wallerian degeneration-slow (Wlds) mouse. Wlds mice
carry a naturally occurring mutation that greatly slows axon
degeneration, allowing axons that are separated from the cell
body to maintain structural and conduction integrity for 2 weeks
after transection in mice (Lunn et al., 1989). In a series of
follow-up studies, it was demonstrated that the slow degeneration
phenotype was intrinsic to the axon (Perry et al., 1990a) and was
controlled by a single autosomal dominant gene (Perry et al.,
1990b; Lyon et al., 1993). It was ultimately determined that the
Wlds gene encodes a chimeric protein, a fusion of the N-terminal
70 amino acids of ubiquitination factor E4B (Ube4b) with
nicotinamide mononucleotide adenylyltransferase-1 (NMNAT1)
(Conforti et al., 2000; Mack et al., 2001). Subsequent research
activity has indicated that the NMNAT1 portion of the fusion
protein is primarily responsible for the Wlds phenotype, as
shown in in dorsal root ganglion culture (Araki et al., 2004).
It is the ATP-dependent activity of NMNAT that converts
nicotinamide mononucleotide (NMN) to NAD+ (Figure 4).
NAD+ is an essential coenzyme in four steps of the Krebs cycle,
an essential cofactor in the GAPDH step of glycolysis, and the
conversion of lactate into pyruvate requires NAD+, reducing it to
NADH. Determining that NMNAT activity contributes to axon
survival after axotomy placed energy as a central issue to the
mechanism of axon degeneration.
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FIGURE 4 | Nicotinamide dinucleotide (NAD+) salvage pathway. NAD+
can be synthesized de novo using tryptophan (not shown), or through a
salvage pathway using vitamin precursors niacin (vitamin B3), nicotinamide
(NAM), or nicotinamide riboside (NR). In the salvage pathway, NMNAT
catalyzes the formation of NAD+ from NMN and ATP. The reverse reaction
converts NAD+ into NMN, giving off ATP. NMN, nicotinamide mononucleotide;
NAD, nicotinamide dinucleotide; NMNAT, nicotinamide mononucleotide
adenylyltransferase; NAMPT, nicotinamide phosphoribosyltransferase.
Given the critical role of NMNAT in axon survival after
injury, logic would dictate that the product of NMNAT activity,
NAD+, is the currency of axon protection. Mammals use
a variant of vitamin B3, nicotinamide, as the precursor for
NAD+ synthesis (Galli et al., 2013) (Figure 4). Roughly 50%
of the pyridine nucleotide NAD+ pool is in mitochondria, and
50% is in the cytoplasm in cultured neurons (Alano et al.,
2010). NADH and NAD+ cannot themselves be transported
into or out of the mitochondria. Cytosolic NAD+ depletion
has been shown to block glucose utilization, consistent with its
requirement in glycolysis. NAD+ is regenerated in cells by the
activity of lactate dehydrogenase, through the electron transport
chain in mitochondria, or the movement of malate and/or
aspartate transport across the inner mitochondrial membrane.
The major consumers of NAD+ in a cell include poly (ADP-
ribose) polymerases (PARPs), and sirtuins (class III histone
deacetylases) (Blander and Guarente, 2004; Belenky et al., 2007).
Strikingly, eliminating two major NAD+ consuming enzymes
(PARP1 and CD38) does not prevent axon degeneration in
mouse sciatic nerve transection (Sasaki et al., 2009). In vivo,
NMNAT1 overexpression was not sufficient for axon protection,
but NMNAT3 targeted to the mitochondrial matrix protected
sciatic nerves after axotomy (Yahata et al., 2009). NMNAT3 likely
regenerates NAD+ in the mitochondria for cellular energetics
(Lau et al., 2009). Since the mitochondrial NAD+ pool is
segregated from the cytoplasmic, NMNAT3-based protection
from degeneration implicates mitochondrial dysfunction in the
energy depletion that contributes to axon degeneration. The
mitochondria isolated from these axons had normal respiratory
chain components but were making more ATP (Yahata et al.,
2009). The centrality of NAD+ in energy production and
utilization suggest a mechanism linking loss of mitochondrial
function to axon degeneration (Di Lisa and Ziegler, 2001).
Mitochondria isolated from Wlds -expressing, protected
mouse axons exhibit increased ATP production (Yahata et al.,
2009) and enhanced Ca++ buffering (Avery et al., 2012).
Importantly, Wlds can ameliorate decreases in ATP after axon
injury in vitro (Wang et al., 2005). There are multiple NMNATs,
each one localized to a cellular compartment. NMNAT1 is
nuclear, NMNAT2 is cytoplasmic and associated with Golgi-
derived vesicles, and NMNAT3 is found in the mitochondria
(Ali et al., 2013). Each of these NAD+-synthesizing enzymes has
been investigated individually and found to impact axon survival.
Mutations in NMNAT1 cause Leber’s congenital amaurosis,
a retinal degeneration disease (Falk et al., 2012). Targeting
NMNAT1 expression to the cytoplasm then inducing ocular
hypertension protects RGCs from death (Zhu et al., 2013).
The protective effect of a cytoplasmic version of NMNAT1
depended upon mitochondrial axon transport (Fang et al.,
2014a). NMNAT2, however, has turned out to be the essential
axon protection factor; when not transported to the axon,
a degenerative program ensues (Gilley and Coleman, 2010).
Mutations that extend the half-life of NMNAT2 increase its
ability to delay axon degeneration, beyond that observed with the
Wlds mutation (Milde et al., 2013). TheWlds protein can protect
a cut axon for up to 4 h in vitro, while NMNAT2 depletion within
5 h commits the axon to degeneration (Gilley and Coleman, 2010;
Wang et al., 2015). The longer half-life of Wlds over NMNAT2
may explain its ability to radically extend axon survival.
Identification of NMNAT2 as an axon protection factor has
been accompanied by identification of two proteins that appear
to be axon death factors (see Figure 5). PHR1, an E3 ubiquitin
ligase, promotes axon degeneration after injury (Babetto et al.,
2013) by influencing the turnover of NMNAT2. PHR1 deletion
delays Wallerian degeneration. SARM1, a Toll-like receptor
adaptor protein tethered to the mitochondria (Kim et al., 2007;
Summers et al., 2014), contributes to axon degeneration such
that its deletion significantly delays Wallerian degeneration after
nerve transection (Osterloh et al., 2012). The mechanism of that
delay includes increased NAD+ synthesis in the axon (Gerdts
et al., 2015). SARM1 activation rapidly breaks down NAD+ after
injury. SARM1 is required for activation of a post-injury MAPK
cascade that disrupts energy homeostasis through ATP depletion
in the axon (Yang et al., 2015). Cut neurites from SARM1−/−
mice showed higher extracellular acidification rate (glycolysis)
and higher maximal respiration than wildtype (Godzik and
Coleman, 2015), suggesting a complex picture of the role of
oxidative phosphorylation and glycolysis in maintaining ATP
levels in injured axons. Isolated neurites show just a partial
view of what is likely happening in vivo, where oligodendrocytes
and astrocytes are capable of contributing to the overall energy
scheme.
The prospect of axon survival has become quite complex with
the further identification of elements capable of contributing
to axon degeneration. Dual leucine zipper kinase (DLK), a
MAP3K upstream of JNK, is necessary and sufficient for RGC
death after optic nerve crush (Welsbie et al., 2013). Inhibiting
the JNK cascade in DLK1−/− sensory neuron cultures delays
Wallerian degeneration (Miller et al., 2009), suggesting that
DLK1 acts through JNK to promote axon degeneration. There
is some disagreement regarding the role of DLK1 in RGCs.
Axon degeneration was not delayed after optic nerve crush
in DLK1-deficient mice (Fernandes et al., 2014). While this
suggests that kinases other than DLK1 may be capable of JNK
activation for axon degeneration, a separate study showed that
phosphorylation of c-Jun, a target of JNK, was dependent on
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FIGURE 5 | NMNAT2 is transported into the axon to support/protect
axon integrity. PHR1, an E3 ubiquitin ligase, can ubiquitinate NMNAT2,
promoting its degradation. This leads to decreases in NAD+, low ATP levels,
and eventual axon degeneration. SARM activation also leads to axon
degeneration through loss of NAD+ and ATP. Ubiquitination-deubiquitination
of PHR1 keeps DLK1 in balance until it is phosphorylated by JNK. DLK1 can
then activate JNK, which phosphorylates SCG10, leading to its degradation.
Axonal degeneration can be blocked by SCG10. Loss of SARM or PHR1
delays degeneration. See text for details.
DLK1 after optic nerve crush (Watkins et al., 2013). DLK1 was
significantly upregulated in post-crush optic nerve and governed
both the pro-apoptotic and pro-regenerative responses of RGCs
(Watkins et al., 2013). JNK works in the commitment phase of
the degeneration cascade since inhibiting it 3 h after axotomy
of mouse or Drosophila axons was not sufficient to prevent
axon loss (Miller et al., 2009). A protein phosphorylated early
after axotomy in the distal segments of sensory nerve, SCG10,
is a microtubule binding protein and JNK substrate whose
phosphorylation targets it for degradation. SCG10 can delay
degeneration of crushed mouse optic nerve if overexpressed
(Shin et al., 2012). Loss of SCG10 alone, however, does not lead
to axon degeneration. JNK regulates SCG10 turnover, linking it
to DLK1. Interestingly, SCG10 is lost after axotomy even when
NMNAT overexpression prevents axon degeneration (Shin et al.,
2012).
After axotomy, PHR1 contributes to NMNAT2 degradation
while SARM1 is similarly contributing to NAD+ depletion
(Figure 5). DLK1 activates JNK, which ensures loss of SCG10.
These events commit an axon to the degeneration cascade, and
it is not yet known how the various elements interact or the
precise timing. There are most certainly modifiers of the cascade
as well as variations by mode of injury and type of neuron, as will
be discussed below. Caveats to the general degeneration scheme
include the fact that some of these mechanisms have been worked
out in vitro, in isolated neurites. While this has established
that Wlds, SARM, and DLK-1 are cell-autonomous in their
impact on axon degeneration, the various unexplained aspects of
degeneration mechanisms are being assiduously investigated.
Glaucomatous Axonopathy: What Form
Does It Take?
The success of axon protection strategies that have emerged
from investigation into the Wlds mutant applied to glaucoma
may enable a determination about the mechanisms of axon
degeneration in this disorder. In Wallerian degeneration, axons
degenerate caudal to a lesion and in an asynchronous way
over a population of axons within a nerve (Waller, 1850).
The nature of the injury dictates its course since Wlds axons
degenerate anterogradely (from the injury toward the synapse)
after transection but retrogradely (from the synapse back toward
the injury) after crush injury in peripheral nerve (Beirowski et al.,
2005). Wallerian degeneration can be triggered even without
physical axonal injury (Ferri et al., 2003; Gilley and Coleman,
2010). In distal axonopathy, for which there is evidence in mouse
models of glaucoma (Schlamp et al., 2006; Crish et al., 2010),
an axon degenerates from the distal-most point and moves
retrogradely. It may be the case that “dying back,” or distal
axonopathy is not separable from Wallerian degeneration in
glaucoma, especially if glaucoma injury resembles a crush injury
with retrograde degeneration. Support for shared mechanisms
of distal axonopathy and Wallerian degeneration comes from
models of Charcot-Marie-Tooth disease, a distal axonopathy that
is significantly slowed by the expression of the Wlds (Meyer
zu Horste et al., 2011). Wlds can also reduce the number of
axon varicosities, enlarged portions of axons containing protein
aggregates that are hallmarks of most neurodegenerative diseases.
Despite this, Wlds cannot delay all axon degeneration (Vande
Velde et al., 2004), and there may be age-related limits to axon
degeneration delay (Samsam et al., 2003). Wlds has been shown
to effectively delay the optic neuropathy of glaucoma in the
mouse (Howell et al., 2007; Beirowski et al., 2008), though it did
not prevent or delay RGC death. A comparison of pre-laminar
and laminar axons (see Figure 6) in the optic nerve head of D2
mice with glaucoma show a significant decrease in axon number
from pre-lamina to lamina, suggesting that axon damage initiates
in the pre-lamina and distal axons degenerate (Howell et al.,
2007). This would be consistent with an anterograde Wallerian
degeneration as observed in transected axons (Beirowski et al.,
2005). However, axon endbulbs can be observed throughout the
optic nerve in the D2 mouse model of glaucoma (Buckingham
et al., 2008; Crish et al., 2010; Dengler-Crish et al., 2014),
suggesting a retrograde degeneration course that would be more
in alignment with the response to crush injury (Beirowski et al.,
2005). Consistent with this, one analysis of D2 optic nerve
showed a distal to proximal pattern of degeneration that preceded
loss of the corresponding RGCs (Schlamp et al., 2006). Without
the ability to monitor the axons along their course, it cannot be
ruled out that the end bulbs and axon fragmentation observed
beyond the optic nerve head are distal portions of axons with an
initiating injury at the optic nerve head.
Neurotrophin deprivation has been considered an important
potential mechanism of RGC decline and death. Manipulating
receptor tyrosine kinase (Trk) signaling concomitant with
growth factor provision has proven to be supportive of RGC
survival (Cheng et al., 2002; Lebrun-Julien et al., 2009; Weber
and Harman, 2013). Developmental axon pruning is an example
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FIGURE 6 | Schematic of the optic nerve head in the mouse. Retinal ganglion cell axons converge at the optic disk and then make a ∼90◦ turn to form the optic
nerve. The pre-lamina region is formed from the fasciculated axons as they traverse the retina. Columns of astrocytes maintain the fasciculated bundles of
unmyelinated axons through the lamina. Beyond the lamina, retinal ganglion axons are myelinated by oligodendrocytes.
of axon degeneration that can be triggered by loss of growth
factor support from target areas. Axon pruning may share
downstream mechanisms of degeneration with post-injury
Wallerian degeneration, but the commitment phase differs. Wlds
cannot prevent pruning in mice or Drosophila (Hoopfer et al.,
2006). Since Wlds mice show normal CNS circuitry instead of
a gross overabundance of unpruned connections, this is not
unexpected. Evidence indicates there may be two mechanisms
by which axons get pruned, one that is caspase-dependent and
the other requiring loss of NAD+; the two may work together
or run parallel to eliminate unneeded circuitry (Schoenmann
et al., 2010). Growth factor deprivation initiates activation of
caspases; Wlds and cytoplasmic NMNAT1, even SARM1 deletion
(Gerdts et al., 2013), can protect against nerve growth factor
(NGF) withdrawal-induced axon degeneration. DLK-1, after
trophic deprivation, is JNK dependent and contributes to both
axon degeneration and cell body apoptosis (Ghosh et al., 2011).
Interestingly, DLK1 knockout in a optic nerve crush model did
not protect RGC axon structure or function as measured by CAP
amplitude (Fernandes et al., 2014), suggesting that degeneration
in these axons is governed differently than those in development
(Hoopfer et al., 2006) and potentially other sensory systems
(Miller et al., 2009). Others determined that deficiency in DLK1
protected RGC somas from apoptosis and proximal axons from
degeneration after optic nerve crush (Watkins et al., 2013).
The pro-apoptotic factor BAX, when deleted in mice of the D2
background, preserved RGC somas but axons degenerated (Libby
et al., 2005). These data indicate that degeneration of the optic
nerve in the D2 model of glaucoma may be caspase-independent.
The preponderance of evidence suggests that glaucomatous
degeneration occurs throughWallerian degeneration rather than
trophic deprivation-related pathways, though the initial kinase
signaling has yet to be determined.
ENERGY AND GLAUCOMA-SPECIFIC
AXON DEGENERATION
RGCs Vulnerable to Energy Depletion
RGCs are not uniformly susceptible to cell death in glaucoma (Li
et al., 2006; Della Santina et al., 2013), and whether specific axons
are particularly vulnerable to degeneration is not known. In the
cat optic nerve, 50% of the axons are in the category of small
and lightly myelinated, and are therefore potentially susceptible
to ATP shortfall. It is believed these axons correspond to γRGCs
(Williams and Chalupa, 1983) which are theW cells by functional
type. W cells include on- or off-tonic, on- or off-phasic, and
on-off phasic cells (Fukuda et al., 1984; Watanabe et al., 1993).
Axon caliber correlates relatively well with soma size (Huxlin
and Goodchild, 1997; Coombs et al., 2006), suggesting that the
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sizable group comprising the slowest conducting axons should
include RGCs with small to medium cell somas. A number of
studies have determined that OFF transient RGCs show early
morphological and functional changes in themicrobead injection
and laser photocoagulation models of glaucoma (Della Santina
et al., 2013; El-Danaf and Huberman, 2015; Ou et al., 2016).
These OFF transients are believed to be αRGCs, those with
large somas and extensive dendritic arbors; however, there are
a number of RGC morphological types with arbor stratification
at 50% of inner plexiform layer (IPL) depth typical of OFF
transient cells (Della Santina and Ou, 2016) that could have
small to medium cell somas and axons possibly in the smaller
ranges. The D2 CAP data (Figure 1) and OFF transient data
are not necessarily in opposition since the traces clearly show
that CAPs are lost from all axon calibers (Baltan et al., 2010);
large αRGCs can be preferentially lost among other cells that also
succumb. Interestingly, after optic nerve transection in mouse,
αRGCs preferentially survive, including OFF transients; when
treated with osteopontin and IGF-1 or by downregulating PTEN,
regeneration only occurs in αRGCs (Duan et al., 2015). Though
αRGCs are a diverse group, it would seem unlikely that cells
particularly susceptible to raised IOP would be resistant to axon
transection.
Mitochondria in Glaucoma
To understand the mechanism of metabolic dysfunction in
D2 optic nerve, the mitochondria would be a reasonable
starting point for investigation since axons obtain most of
their energy from ATP through oxidative phosphorylation.
One very relevant study determined that mitochondria isolated
from patients resistant to optic neuropathy—exposed to
high IOP but absent pathology—showed greater levels of
systemic “mitochondrial efficiency,” including higher rates of
ADP phosphorylation, hyperpolarized mitochondrial membrane
potential, and enhanced Ca++ buffering capacity compared to
control and glaucoma patient groups (Lascaratos et al., 2015).
These observations single out the mitochondrial function as
a potential biomarker for individuals susceptible to increased
IOP. Our electron microscopic analysis of mitochondria in
the D2 optic nerve is consistent with lower mitochondrial
support in glaucoma patients. We observed a linear relationship
between mitochondrial volume and axon volume in DBA/2J-
Gpnmb+ (control strain that does not develop glaucoma) and
pre-pathological D2 optic nerve. That relationship is abolished
in the transport dysfunctional D2 optic nerve, for which we
observed axon volumes that were not matched by appropriate
mitochondrial volumes (Kleesattel et al., 2015). Interestingly,
CAP amplitude measures suggest that the third peak of the
CAP trace, corresponding to the slowest conducting axons, are
lost earliest and in the greatest numbers, and in accordance to
magnitude of IOP exposure, in the D2 mouse model of glaucoma
(see Figure 1; Baltan et al., 2010).
What ties metabolism to susceptible RGCs? In short, very
little is directly known about the specifics of OFF transient cell
energy homeostasis, though mitochondrial distribution could be
a factor. Whereas mitochondria take up greater axon volume in
unmyelinated axons, lightly myelinated axons in mouse (Ohno
et al., 2011) and guinea pig have slightly fewer mitochondria
than predicted (Perge et al., 2009). Mitochondria in the D2 optic
nerve are significantly smaller and possess reduced cristae with
aging and increased IOP (Coughlin et al., 2015); this supports
widespread fission of these organelles, as has been observed by
others (Ju et al., 2008). Smaller mitochondria with reduced cristae
have less machinery for oxidative phosphorylation, and therefore,
lower energetic capacity. This would spell particular trouble if
the optic nerve were ever to experience glucose shortage (for
example, if glucose transporters were downregulated) because
functional mitochondria are required for an axon to survive on
lactate. Lactate conversion to pyruvate bypasses glycolysis. The
resultant pyruvate is converted to acetyl-CoA for use in Krebs
cycle (Figure 3). The intermediates produced there are used to
establish the electron transport chain and the protonmotive force
for ATP Synthase (Complex V) and ATP production. Hence,
survival on lactate requires functional mitochondria.
Unfortunately for axon survival, poorly functioning
mitochondria are not being efficiently recycled in the D2
optic nerve (Coughlin et al., 2015). By not being replaced,
these mitochondria can contribute to metabolic vulnerability by
producing lower levels of ATP and comparatively more reactive
oxygen species (ROS). Mitochondrial biosynthetic proteins such
as PGC-1α decrease with age, including in the retina of D2 mice
(Guo et al., 2014). Low PGC-1α levels likely limit mitochondrial
biogenesis. With no prospect of generating new mitochondria,
the lack of recycling of malfunctioning organelles is likely a
survival mechanism.
Investigating the impact of upregulating mitophagy in
glaucoma could resolve whether maintaining compromised
mitochondria can ensure continued, albeit weakened, axon
function. Some insight can be gleaned from a study in which
autophagy was inhibited in glaucoma using 3-methyladenine
(Seglen and Gordon, 1982). The authors observed significant
axon degeneration after inhibiting autophagy, and axon
protection when promoting autophagy through rapamycin
treatment (Kitaoka et al., 2013). Conflicting results have
accompanied those examining the role of autophagy in
glaucoma, with autophagy induction detrimental to RGC soma
survival in an ocular hypertension glaucoma model (Park et al.,
2012), but rapamycin-induced autophagy protective of RGC
somas after axotomy (Rodriguez-Muela and Boya, 2012).
Glial Cells
As outlined above, astrocytes and oligodendrocytes can exert
significant control over the availability and utilization of energy
in the optic nerve. Analyses of optic nerve head and axonal
glia in glaucoma to date have focused on morphological change
(Lampert et al., 1968; Dai et al., 2012; Sun and Jakobs, 2012;
Lye-Barthel et al., 2013; Bosco et al., 2016; Cooper et al.,
2016), or cell loss. In the D2 optic nerve, astrocyte hypertrophy
occurred early in the disease process and was maintained;
oligodendrocytes were lost only after axon loss (Son et al., 2010).
Alternatively, a model of laser induced ocular hypertension
led to significant oligodendrocyte loss within 1 week of IOP
elevation (Nakazawa et al., 2006). Oligodendrocyte loss could
be ameliorated with an antibody against TNFα, suggesting a
Frontiers in Neuroscience | www.frontiersin.org 9 March 2017 | Volume 11 | Article 146
Inman and Harun-Or-Rashid Metabolic Vulnerability in Glaucoma
role for microglial-associated inflammation in the loss of myelin.
Specific attributes of oligodendrocytes in glaucoma have not
been investigated, though NG2+ cells proliferate and generate
new oligodendrocytes after axon degeneration in the optic nerve
(Son et al., 2010). In considering what is understood about
the other macroglial cell in the optic nerve during glaucoma,
the relationship between astrocyte hypertrophy and metabolic
support of axons is unknown. These knowledge gaps provide
many fertile areas of investigation for the metabolic role of optic
nerve glia in glaucomatous neurodegeneration.
ADDRESSING ENERGY FAILURE IN
GLAUCOMA
Glaucoma is an asynchronous degeneration of the optic nerve.
Does axon degeneration occur from loss of protection factors
or activation of death factors, or is it both? Where and when
does energy dysregulation occur? How does one support axons
before they fail? One approach to prevent axon degeneration is
to develop ways to target cells that are likely to succumb. As
noted above, specific RGCs and compartments seem particularly
susceptible. As research refines the susceptible populations,
targeting strategies can also become more sophisticated, though
certain protection strategies may show positive consequences
to targeting all RGCs. Aging remains an important risk factor,
as suggested by the significant decreases in ATP with age
(Figure 1) as well as degree of IOP exposure. Various energy-
related approaches have been used to prevent axon degeneration
in models of neurodegeneration, including providing creatine,
manipulating members of the NAD+-sirtuin-PGC1α axis, and
upregulating the NMNATs. Strategies used to protect against
axon degeneration in glaucoma in particular consist of providing
glucose, upregulating NMNAT1 andNMNAT3, providing ketone
bodies, and inhibiting histone deacetylases (HDACs).
Glucose
Protection from glaucoma-induced optic neuropathy can
occur by increasing energy substrates such as glucose. In a
rat laser photocoagulation model of glaucoma, induction of
hyperglycemia 4 days prior to ocular hypertension was shown
to decrease axon loss in the optic nerve by more than 50% and
increase ganglion cell survival also by roughly 50% (Ebneter et al.,
2011). While glial activation was decreased in the optic nerve,
retinal glial showed comparable levels of reactivity (microglia
and astrocytes/Müller glia). A caveat to this study included the
relatively brief study period (2 weeks) (Ebneter et al., 2011).
Longer periods of hyperglycemia (6 weeks to 3 months) after
ocular hypertension did not show neuroprotection in the retina
(Kanamori et al., 2004a), though a distinction between neuronal
and glial cell death was not made. A critical issue with increasing
blood glucose levels is that hyperglycemia does not necessarily
translate into greater glucose availability to the CNS without
matching levels of high affinity glucose transporters such as
GLUT3, or GLUT1. Whereas GLUT1 appears to be upregulated
by NMDA-R activation (Saab et al., 2016), insulin can promote
translocation of GLUT1 and GLUT3 to the cell surface (Uemura
and Greenlee, 2006). In chronic glaucoma models, the likelihood
of NMDA-R activation sufficient to upregulate GLUT1 seems
unlikely because RGCs generally fire at low rates (more than
90% fire at 10 Hz or less) (Koch et al., 2004), and axons are being
lost. The ectopic glutamate release observed in the optic nerve
head in one glaucoma model (Fu and Sretavan, 2012) would
not be directed at oligodendrocytes because axons in the nerve
head are unmyelinated, but might its target be laminar astrocytes
in an attempt to upregulate glucose transporters? Episcleral
cauterization to initiate ocular hypertension in rats led to
increased insulin and insulin-like growth factor receptor levels,
concomitant with phosphorylated Akt, in retina in the acute
post-injury period (Kanamori et al., 2004b). In the R28 rat retina
neural cell line subjected to serum deprivation, insulin has been
shown to be a retinal neuron survival factor by acting through
the PI3K-Akt signaling pathway to decrease caspase-3 activation
(Barber et al., 2001). It is unknown if glucose transporters were
upregulated by these insulin increases. Traumatic brain injury,
known to result in an 8-fold increase in extracellular lactate
(Nilsson et al., 1990), led to an increase in neural (GLUT3), but
not glial (GLUT1) glucose transporters (Hamlin et al., 2001).
This would be consistent with increased need for energy in the
neural compartment.
Glycogen
Astrocytes are the primary storage location for glycogen (Cataldo
and Broadwell, 1986). Glycogen is broken down to glucose,
but studies have shown that glycogen mobilization in astrocytes
provides lactate, not glucose, to the extracellular milieu (Dringen
et al., 1993). During periods of aglycemia, astrocytic glycogen
is rapidly depleted, able to sustain function for no more
than a few minutes (Brown, 2004). Increasing glycogen stores,
though, can maintain axon firing longer during periods of
hypoglycemia in rat brain (Suh et al., 2007). Astrocytes form
the glia lamina of the optic nerve head in rodents (Figure 6),
and these cells undergo profound morphological change with
ocular hypertension (Sun et al., 2009; Dai et al., 2012; Bosco
et al., 2016; Cooper et al., 2016). Of note, the optic nerve
head glia impacted by glaucoma no longer contact the basal
lamina of the nerve (Dai et al., 2012), the ultrastructural location
of glycogen granules (Brown, 2004). This suggests astrocyte
glycogen might be a source of metabolic vulnerability in the
glaucomatous optic nerve due to possible depletion. Increasing
glycogen stores, however, may not make a significant difference
to energy homeostasis in a chronic disease like glaucoma because
of its rapid depletion. Glycogen has other potential roles though,
such as support of glutamatergic neurotransmission (Obel
et al., 2012). Glycogen production through glycogen synthase is
regulated by three kinases, including glycogen synthase kinase
3 (GSK-3). GSK-3 in particular has probable implications for
glaucoma through its targets and its promiscuity; GSK-3 has
more predicted substrates than any other kinase (Linding et al.,
2007). GSK-3 phosphorylation regulates transcription factors
such as NF-κB, STAT3, Fos/Jun AP-1, p53 (Beurel et al., 2015);
histone deacetylases; and proteins like the microtubule binding
tau (Mandelkow et al., 1992), critical to Alzheimer’s disease
and neurodegenerative disease pathology (Stamer et al., 2002;
Frontiers in Neuroscience | www.frontiersin.org 10 March 2017 | Volume 11 | Article 146
Inman and Harun-Or-Rashid Metabolic Vulnerability in Glaucoma
Mandelkow et al., 2003). It is as yet unknown whether a
connection exists between astrocyte glycogen production and
neurodegenerative disease pathology through GSK-3.
Creatine
Ischemia is also postulated to occur as a result of poor
blood flow at the optic nerve head, as observed in glaucoma
patients (Schwartz, 1994; Grunwald et al., 1998); it also occurs
in models of acute IOP increase (Sun et al., 2010). ATP
turnover in cells is fast, but more so in tissues subjected to
ischemia. ATP supply is maintained by a pool of phosphocreatine
that exists at sites of high energy consumption because
phosphocreatine can be converted by creatine kinase into ATP
+ creatine more quickly than ATP can be generated. Creatine
is neuroprotective in many models of hypoxia, including
for cerebral ischemia when delivered intercerebroventricularly
(Lensman et al., 2006), and after experimental stroke when
the creatine is in a formulation that extends half-life (Perasso
et al., 2009). Pre-treating cortical axons with creatine prevented
ischemia-induced damage as well as alleviating ATP depletion
(Shen and Goldberg, 2012). This protection was independent of
glial cells. Nevertheless, protection from ischemia corroborated
previous studies demonstrating that creatine is not effective when
delivered post-ischemia injury (Lensman et al., 2006; Shen and
Goldberg, 2012). It may be the case that sufficient levels of
creatine could not be delivered in a timely manner to counteract
the depolarization and subsequent energy depletion in ischemia.
NMNATs
Similar to studies in sensory neurons, NMNATs have significant
impact on RGCs and their axons. Embryonic mice (E18.5)
nullizygous for NMNAT2 showed truncated RGC axons; the
axons did not reach the optic chiasm, and there was no optic
tract. RGC bodies appeared normal, with proximal axons that
formed the optic nerve (Gilley et al., 2013). These results
suggested a developmental role for NMNAT2 in axon extension.
NMNAT3 upregulation in two different mouse models of
glaucoma exerted significant protection of axons that could be
reversed with treatment by 3-methyladenine, a PI3K inhibitor
that reduces autophagy (Kitaoka et al., 2013). Cytoplasmic
NMNAT1 upregulation protected RGC somas and axons in
models of retinal ischemia and ocular hypertension (Zhu et al.,
2013). The studies did not thoroughly examine the mechanism
of NMNAT protection, though the apparent connection to
autophagy in the Kitaoka study suggests that recycling of all but
the most basic cellular components can help maintain energy
homeostasis in RGCs subjected to pressure-induced insult.
NAD+-Sirtuin-PGC-1α Axis Manipulation
NAD+ levels decrease with aging (Guarente, 2014), and
various studies of NAD+ replenishment (either direct or
through precursors) demonstrated better metabolic health and
mitochondrial function in diet-related diabetes (Yoshino et al.,
2011), and in muscle stem cells in aged mice (Zhang et al.,
2016). After axotomy in vitro, exogenous application of NAD+
was sufficient to slow the degeneration (Wang et al., 2005).
Thus, a successful strategy for slowing or preventing axon
degeneration has been to indirectly provide energy (Araki et al.,
2004; Chung et al., 2013). Wallerian degeneration, the most
likely mechanism by which glaucomatous RGC axons die, can be
halted through increased NAD+ biosynthesis (Araki et al., 2004)
and the action of a serine protease inhibitor that prevents ATP
decrease (Ikegami et al., 2004). Despite NAD+ being an obvious
candidate effector for axon protection, overexpression of Wlds
and NMNAT prevents axon degeneration but does not increase
basal NAD+ levels (Mack et al., 2001; Araki et al., 2004), and
NAD+ levels are not essential to axon preservation (Sasaki et al.,
2009). If NAD+ levels are dispensable, then perhaps it is ATP
levels that are crucial to axon protection. Reducing axon ATP
causes irreversible axon damage (Shen et al., 2013).
NMNAT overexpression has had some success in models of
glaucoma (Kitaoka et al., 2013), though if energy support is
the goal, a very promising candidate is the NAD+ precursor
nicotinamide riboside (Figure 4). Nicotinamide riboside (NR),
when orally delivered to humans and mice, exhibits superior
bioavailability and pharmacokinetics than either nicotinamide
or nicotinic acid. NR significantly increases NMN, NAM, and
NAD+ levels in humans by the fourth dose of a daily 1,000mg
intake, and maintains those increases up to 24 h after the seventh
dose (Trammell et al., 2016).
Sirtuins
The sirtuins, class III histone deacetylases (HDACs), have had
variable impact on degeneration in the CNS, their activation
effective at delaying neurodegeneration in some situations, but
not all (Conforti et al., 2007). Indirect maintenance of NAD+
pools through HDAC inhibition has been demonstrated in
neurodegenerative diseases (Langley et al., 2005). In a transgenic
mouse model of Alzheimer’s disease, nicotinamide treatment
inhibited SIRT1 activity, reduced phosphorylated tau, and
restored cognitive ability (Green et al., 2008). As was discussed
above, PARP1 and SIRT1 are enzymes that require NAD+ for
activity. PARP1 inhibition or elimination did not improve axon
regeneration after optic nerve transection in mice (Wang et al.,
2016), though treatment started 3 days after injury and there
is only a few hours between injury and commencement of
Wallerian degeneration.
Resveratrol, a SIRT1 activator, has been utilized as a
tool to probe the complexities of SIRT1 and degeneration.
Resveratrol delayed Wallerian degeneration in sensory neuron
cultures and after sciatic nerve crush (Calliari et al., 2013).
The degeneration delay could be blocked by eliminating an
endogenous SIRT1 inhibitor, DBC-1. DBC-1 knockout nerves
degenerated just as quickly as wildtype if NAD+ was not present,
indicating that NAD+ was necessary for full SIRT1 activity and
subsequent axon protection (Calliari et al., 2013). Resveratrol
also induced phosphorylation of AMPK, a master regulator
of energy homeostasis (Dasgupta and Milbrandt, 2007), which
when activated, stimulates glucose uptake in the brain (Hardie
et al., 2012).
Resveratrol increased mitochondrial number and improved
mitochondrial function primarily through SIRT1 deacetylation
of PGC-1α and subsequent increased PGC-1α activity in mice
(Lagouge et al., 2006). These effects were observed in skeletal
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muscle and adipose tissue. In the CNS, resveratrol was found
to increase brain lactate production and limit movement of
radiolabeled pyruvate through Krebs cycle, thereby limiting
oxidative phosphorylation (Rowlands et al., 2015). Is limiting
oxidative phosphorylation a viable approach for preventing axon
degeneration? The variable impact (positive and negative) of
SIRT1 onWallerian degeneration indicates the likelihood that the
timing and overall energy state of the system dictate the response
to SIRT1 activation. Blocking oxidative phosphorylation would
limit ROS production, though blocking mitochondrial function,
especially if axons are being supported by glial-derived lactate,
would seem to be a risky approach.
SIRT1 manipulation has not been wholly favorable in
glaucoma-related models. SIRT1 overexpression promoted RGC
survival after optic nerve crush in mouse, an effect that was more
pronounced than resveratrol treatment (Zuo et al., 2013). SIRT1
knockout did not increase RGC death over wildtype mice after
optic nerve crush, suggesting complex interactions of cell death
mechanisms. Moreover, functional testing of the RGCs showed
no difference among the SIRT1 activation, overexpression, or
knockout groups, suggesting that axon degeneration occurred
regardless of SIRT1 status (Zuo et al., 2013). The SIRT1
downregulation that resulted from 60 min of retina ischemia in
mice could be reversed with once daily mangiferin treatment,
a xanthonoid antioxidant (Kim et al., 2015). Resolution of the
potential impact of manipulating these key regulators of energy
homeostasis in glaucomawill require closer investigation in order
to determine if they might be reasonable therapeutic targets.
Mitochondria
Upregulating mitochondrial biogenesis would provide more
energy-producing organelles to susceptible RGCs, but may
place stressors on protein synthesis machinery, especially with
aging. Greater numbers of mitochondria would still need to
get trafficked along the axon, which may pose a significant
problem depending on the stage of glaucoma. One regulatory
complex important for mitochondrial biogenesis, mTOR, was no
different in tissues between patients with ocular hypertension
(OHT) and those with glaucoma (Lascaratos et al., 2015) even
though the OHT patients demonstrated increased mitochondrial
efficiency and no optic neuropathy. No change in mTOR
suggests that the advantage conferred to OHT patients resistant
to optic neuropathy did not include a drive toward making
more mitochondria. Rather than make more mitochondria, a
better strategy could be to improve mitochondrial function.
Compensation for impaired oxidative phosphorylation in OPA1-
linked autosomal dominant optic atrophy (ADOA) patients has
been associated with preservation of vision (van Bergen et al.,
2011). Complex II and III activity was higher in ADOA patients
with better vision, and these patients had higher respiration
rate. Improving mitochondrial function has been the asserted
outcome for many of the abovementioned axon protection
strategies such as insulin-associated PI3K/Akt activation, SIRT1
activation, and antioxidant treatment. The variable outcomes
with these treatments suggest more specific changes as opposed
to generalized improved mitochondrial function are necessary.
Mitochondrial Biogenesis
If unhealthy mitochondria contribute to glaucoma pathogenesis,
ridding RGCs of the ROS-producing organelles would have
to be coupled with mitochondrial biogenesis. A number
of other neurodegenerative disease models have manipulated
mitochondrial recycling or production to neuroprotective effect.
Increased DNA damage response through hyperactivation of
PARP-1 [poly (ADP-ribose) polymerase-1] can inhibit mitophagy
by disrupting the NAD+-sirtuin-PGC-1α axis in cells developed
from xeroderma pigmentosum group A patients (Fang et al.,
2014b). Mitophagy in this context can be rescued by upregulating
mitochondrial uncoupling protein 2 (UCP2) or providing the
NAD+ precursors nicotinamide riboside (NR) or nicotinamide
mononucleotide (NMN). Resumption of mitophagy reduced
mitochondrial mass, but also reactive oxygen species in
cultured hippocampal neurons subjected to H2O2 or oxygen
glucose deprivation (Fang et al., 2014a). Upregulation of
UCP2, a target of PGC-1α, increases ATP levels, reduces
ROS and can protect neurons from mitochondrial Complex
I disruption in a Drosophila model of Parkinson’s disease
(Islam et al., 2012). However, UCP2 overexpression in the
G93A SOD1 mouse model of ALS led to lower levels of
ROS but acceleration of the disease course (Peixoto et al.,
2013). The proton conductance function of UCP2 requires
the presence of specific activators that include fatty acids and
ROS-derived alkenals (Brand and Esteves, 2005), the lack of
which might explain why UCP2 overexpression is not always
protective. Necdin, a protein that binds SIRT1, can stabilize PGC-
1α and inhibit its ubiquitin-dependent degradation, thereby
enhancing mitochondrial biogenesis (Hasegawa et al., 2016). The
neuroprotection against mitochondrial-related injury afforded by
necdin resembles that shown by PGC-1α upregulation (Mudò
et al., 2012).
Ketone Bodies
Insight into the potential role of metabolism in the pathogenesis
of glaucoma has emerged from several recent studies. In the
EAAC1−/− model of normal tension glaucoma, every-other-
day-fasting (EODF) led to significant protection of FluoroGold-
positive retrogradely labeled RGCs, as well as the b wave
of multi-focal ERG (Guo et al., 2016). EODF appeared to
exert its effects through elevated β-hydroxybutyrate (β-HB), a
ketone and endogenous histone deacetylase (HDAC) inhibitor.
Increased β-HB levels led to increased histone acetylation
that occurred concomitantly with increased mRNA expression
of BDNF, bFGF, and catalase (Guo et al., 2016). β-HB can
inhibit the class I HDACs (HDAC1, 2, 3, and 8) and at
least one class II HDAC (HDAC4) (Shimazu et al., 2013).
Ketogenic or medium chain fatty acid diets that lead to
high levels of β-HB have long been effective at controlling
seizure in children with epilepsy (Yellen, 2008), and have
also demonstrated neuroprotection in models of Parkinson’s
disease (Yang and Cheng, 2010), Alzheimer’s disease (Henderson
et al., 2009), and ALS (Zhao et al., 2006). An important
question is whether increasing ketone levels and subsequent
manipulation of energy pathways is responsible for the observed
neuroprotection, or if the results can be ascribed particularly
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to the inhibition of histone acetylation. Inhibiting HDACs
has been mostly effective at limiting damage in models of
glaucoma. For example, inhibiting HDAC3 protected RGCs
from death after optic nerve crush (Schmitt et al., 2014), and
HDAC inhibition with valproic acid protected RGCs from
death and preserved pERG amplitude in a rat model of
ocular hypertension (Alsarraf et al., 2014). A broad HDAC
inhibitor, trichostatin A, when delivered to D2 mice weekly for
4 months, did not protect the optic nerve from degeneration
(Pelzel et al., 2012). What of the possibility that β-HB limits
damage because it is a ketone body? Ketone bodies get
converted into acetyl-CoA for utilization in the Krebs cycle
(Figure 3), the biosynthetic hub whose intermediates provide
the building blocks for fatty acids, nucleotides and the carbons
for gluconeogenesis. In the near term, then, increased levels of
monocarboxylates like ketone bodies would require the Krebs
cycle and oxidative phosphorylation for energy generation.
In mammals, more lactate could feed the production of
glucose through gluconeogenesis, though this is an energy-
expending process. L-lactate can protect cortical neurons from
excitotoxic cell death in vitro (Llorente-Folch et al., 2016);
this effect depends upon the aspartate-glutamate carrier in
CNS mitochondria, ARALAR/AGC. This carrier is one half
of the malate-aspartate shuttle that moves malate/aspartate
and α-ketoglutarate/glutamate between the cytoplasm and the
mitochondria in order to regenerate NAD+ from NADH in
both compartments. Neuronal utilization of L-lactate depends
on the this pathway (Llorente-Folch et al., 2016), underscoring
the importance of NAD+ availability to managing the effects
of too much NMDA receptor activation. This is one potential
mechanism of ketone body neural protection that is separate
from HDAC inhibition.
RESOLVING METABOLIC VULNERABILITY
Aging is a primary risk factor in glaucoma. There is recognition
across neurodegenerative diseases that glucoregulatory control
decreases with aging, spawning clinical trials designed to
ameliorate the effects of aging through the use of compounds
like metformin (ClinicalTrials.gov Identifier: NCT02432287) or
acarbose (Brewer et al., 2016). These trials do not address
glaucoma in particular, but may impact the disease through
improved glucoregulatory control. Serum citrate as a potential
biomarker for glaucoma was the subject of a recently completed
clinical trial that showed significantly decreased citrate in the
serum of Caucasian glaucoma patients (Fraenkl et al., 2011).
Citrate is a byproduct of the Krebs cycle, so decreased values
support the idea that mitochondrial function is impaired in
glaucoma patients. Mitochondrial function can be monitored in
patient retinas using the green fluorescence emitted by oxidized
flavoproteins, a byproduct of oxidative stress (Field et al., 2011).
This development may improve diagnosis as well as provide a
means to monitor future metabolic therapy.
The complexity of optic nerve degeneration in glaucoma—
its chronic timing, its asynchronicity, its non-cell autonomous
nature—presents many challenges to medicine. Having reviewed
the various ways energy plays a role in axon degeneration, we
have also summarized several metabolic-related mechanisms of
protection. The evidence indicates energy plays a critical role in
the timing and organization of axon degeneration, including in
glaucoma.
Note Added in Proof
Significant RGC soma and axon protection from glaucoma-
related degeneration in the D2 mouse was achieved through
dietary supplementation of nicotinamide (Williams et al., 2017).
The finding is quite robust, with significant protection at both
low (550 mg/kg/day) and high levels (2,000 mg/kg/day) of
nicotinamide delivery. The study used RNA-sequencing to show
a reversion of gene expression to that demonstrated by the
control strain, DBA/2-Gpnmb+, across clusters of genes that
included those involved in oxidative phosphorylation; reactive
oxygen species, glucose, and fatty acid metabolism; and DNA
repair. These results support the existence of a metabolic
vulnerability in glaucoma; the mechanism of protection is yet to
be elucidated.
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